Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence of native GHRH with the addition of a trans-3-hexenoic acid group at the N-terminus. This modification stabilizes the peptide against DPP-IV cleavage at the Ala2 position, extending its biological activity compared to native GHRH while preserving the full receptor-binding sequence.

Tesamorelin is one of the most clinically studied GHRH analogs, having been evaluated in multiple Phase III clinical trials for HIV-associated lipodystrophy (HALS), a condition characterized by visceral fat accumulation. These studies, which led to FDA approval of tesamorelin injection (Egrifta) for HALS in 2010, provide a substantial body of pharmacodynamic data characterizing the compound's effects on the GH axis in human subjects. The clinical data make tesamorelin an important reference compound in GH axis research.

Beyond lipodystrophy research, tesamorelin has been studied in models of cognitive aging. Investigators at Vanderbilt University and other institutions conducted trials examining tesamorelin's effects on executive function and memory in older adults with mild cognitive impairment, with findings suggesting improved performance on cognitive testing and reduced cortical amyloid burden in some analyses. These results have positioned tesamorelin as a research tool in neurodegenerative disease models.

Tesamorelin is available for laboratory research applications. Researchers have access to an unusually rich clinical dataset compared to most research peptides, enabling translation of preclinical findings to established human pharmacodynamic parameters.